Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AA21004 versus agomelatine in adults with major depressive disorder and inadequate response to prior SRI monotherapy
2011-002362-21Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Lu AA21004 flexible dose with Agomelatine flexible dose (2 arms). Primary endpoint: Change in MADRS total score from baseline to Week 8. Started Oct 2011; status: completed.
02
Drugs
vortioxetineagomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2011-002362-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002362-21.